Australia seems poised to gain access to innovative therapy for obesity: Retatrutide. This dual molecule – acting on both GLP-1 and GIP receptors – has promising outcomes in clinical studies, indicating meaningful decreases in BMI. While approval hasn't occurred with Australian regulators, several people struggling being overweight could consid